These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11818491)

  • 1. Rational approach to AIDS drug design through structural biology.
    Wlodawer A
    Annu Rev Med; 2002; 53():595-614. PubMed ID: 11818491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design of AIDS drugs and the development of resistance.
    Wlodawer A
    Vox Sang; 2002 Aug; 83 Suppl 1():23-6. PubMed ID: 12617097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New strategies for structure-guided design of AIDS antivirals.
    Blundell TL
    Prog Biophys Mol Biol; 2005 Jun; 88(2):191-2. PubMed ID: 15572154
    [No Abstract]   [Full Text] [Related]  

  • 4. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Das K; Lewi PJ; Hughes SH; Arnold E
    Prog Biophys Mol Biol; 2005 Jun; 88(2):209-31. PubMed ID: 15572156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural mechanisms of HIV drug resistance.
    Erickson JW; Burt SK
    Annu Rev Pharmacol Toxicol; 1996; 36():545-71. PubMed ID: 8725401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive inhibitors of the HIV-1 protease.
    Ohtaka H; Freire E
    Prog Biophys Mol Biol; 2005 Jun; 88(2):193-208. PubMed ID: 15572155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
    Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
    Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 protease inhibitors: a comparative QSAR analysis.
    Kurup A; Mekapati SB; Garg R; Hansch C
    Curr Med Chem; 2003 Sep; 10(17):1679-88. PubMed ID: 12871116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 reverse transcriptase inhibitors.
    El Safadi Y; Vivet-Boudou V; Marquet R
    Appl Microbiol Biotechnol; 2007 Jun; 75(4):723-37. PubMed ID: 17370068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drugs for old.
    Winston A; Stebbing J
    J HIV Ther; 2005 Mar; 10(1):11-6. PubMed ID: 15951729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can we design drugs for HIV/AIDS that are less susceptible to resistance?
    Weber IT
    Future Med Chem; 2015; 7(17):2301-4. PubMed ID: 26619140
    [No Abstract]   [Full Text] [Related]  

  • 12. Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs.
    Sarafianos SG; Hughes SH; Arnold E
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1706-15. PubMed ID: 15183339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advances in novel anti-HIV-1 drugs and drug candidates: 2005-2008].
    Zheng PR; Xue H; Xiao ZY; Liu G
    Yao Xue Xue Bao; 2010 Feb; 45(2):154-64. PubMed ID: 21351426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets.
    Kang D; Song Y; Chen W; Zhan P; Liu X
    Mol Biosyst; 2014 Aug; 10(8):1998-2022. PubMed ID: 24841339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The prevalence of HIV-1 drug resistance and associated factors in AIDS patients receiving HAART in Zhecheng county, Henan province].
    Yuan Y; Xing H; Wang XY; Liu CH; Yang LT; Zheng BF; Wang X; Ruan YH; Wang Z; Liu HW; Shao YM
    Zhonghua Yu Fang Yi Xue Za Zhi; 2011 Jul; 45(7):619-24. PubMed ID: 22041566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggressive HIV-1?
    Berkhout B; de Ronde A; van der Hoek L
    Retrovirology; 2005 Feb; 2():13. PubMed ID: 15737238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of anti-HIV-1 drugs.
    Lu XF; Chen ZW
    Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [HIV-1 resistance against antiretroviral agents].
    Asjø B; Ulvestad E
    Tidsskr Nor Laegeforen; 2001 Nov; 121(29):3421-4. PubMed ID: 11826790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug failure during HIV-1 treatment. New perspectives in monitoring drug resistance.
    Re MC; Bon I; Monari P; Gorini R; Schiavone P; Gibellini D; La Placa M
    New Microbiol; 2003 Oct; 26(4):405-13. PubMed ID: 14596353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.